VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Hudis on the Optimism Surrounding Immunotherapy

Clifford A. Hudis, MD
Published: Friday, Sep 27, 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Hudis says following the 2012 ASCO Annual Meeting, this is the second year of active manipulation of the immune system as a way of treating refractory diseases like melanoma. Now, there is substantial evidence that combinations of drugs can activate the immune system and be effective.

Hudis is optimistic about the narrow application of immunotherapy in metastatic melanoma, a difficult-to-treat disease, because data now indicates the ability to treat a variety of metastatic solid tumors.

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Hudis says following the 2012 ASCO Annual Meeting, this is the second year of active manipulation of the immune system as a way of treating refractory diseases like melanoma. Now, there is substantial evidence that combinations of drugs can activate the immune system and be effective.

Hudis is optimistic about the narrow application of immunotherapy in metastatic melanoma, a difficult-to-treat disease, because data now indicates the ability to treat a variety of metastatic solid tumors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x